Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB5005 in CD19-positive Relapsed/Refractory B-NHL
NCT06875063Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2026
- Primary completion
- May 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB5005 in B-cell non-Hodgkin lymphoma (4 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Remission up to 3 months. Started Apr 2026; status: recruiting.
02
Drugs
GB5005
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06875063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875063.